Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform
Verastem's AVMAPKI FAKZYNJA generated $43.7 million of H1 2026 revenue, funding its KRAS G12D oncology pipeline ahead of an October VS-7375…
Equity Eagle 2 clicksNASDAQ
Verastem, Inc.
VSTM
1 story
$783M Market cap · 2026-10-16
Equity Eagle 2 clicks